Baricitinib for hard-to-treat uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a pill called baricitinib (Olumiant) for people with uveitis (inflammation inside the eye) that hasn't improved with other biologic treatments. It aims to reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have uveitis that affects the middle or back part of your eye (not just the front).
- Your uveitis is not caused by an infection.
- You have already tried at least one biologic medicine (like anti-TNF or tocilizumab) and it didn't work well enough.
- You must stop your current biologic and other immune-suppressing medicines at least 10 days before starting the study.
- You have not had certain eye treatments recently, like steroid injections or implants.
- You have no history of blood clots in your veins or cancer in the last 5 years (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This study tests a pill called baricitinib (already used for arthritis) to see if adding it to your HIV medications can help control the virus long-term. You might join if your HIV is well controlled and you are generally healthy.
This study tests whether adding the drug baricitinib to standard clot-removal treatment for a certain type of stroke improves recovery. It aims to see if the drug reduces inflammation in the brain and leads to better outcomes.
This trial tests a new drug called tulisokibart for people with active inflammation in the back of the eye (uveitis). The drug may help reduce inflammation and prevent vision loss.
Hear when a new Active Non-anterior Non-infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.